1 points | by randycupertino 9 hours ago ago
1 comments
Exciting results for this rare genetic muscle-wasting disorder Limb-Girdle Muscular Dystrophy (LGMD2I/R9) trial, and sounds like the FDA is on board with the surrogate endpoint. Could be big validation for BridgeBio’s rare disease strategy.
Exciting results for this rare genetic muscle-wasting disorder Limb-Girdle Muscular Dystrophy (LGMD2I/R9) trial, and sounds like the FDA is on board with the surrogate endpoint. Could be big validation for BridgeBio’s rare disease strategy.